ArticleBMC cancer2016
The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer.
Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Prevalence of human papillomavirus and its prognostic value in vulvar cancer: A systematic review and meta-analysis.PloS one · 2018Pooled it
- Intranasal verrucous carcinoma with autoinoculation from benign warts in the context of locus minoris resistentiae.Wiener medizinische Wochenschrift (1946) · 2026Article
- TP53 codon 47 and 72 polymorphisms show no association with HPV in Zimbabwean women living with HIV and histologically confirmed cervical and vulvar disease.Frontiers in reproductive health · 2026Article
- Prognostic impact of p16 and high-risk HPV DNA in ~1300 patients with vulvar cancer.International journal of cancer · 2025Article
- Prognostic value of HPV-PCR, p16 and p53 immunohistochemical status on local recurrence rate and survival in patients with vulvar squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2024Article
- Review effects of radiation treatment on HPV-related vulvar cancer: a meta-analysis and systematic review.Frontiers in oncology · 2024Review
- Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis.Journal of clinical medicine · 2022Review
- Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth.Journal for immunotherapy of cancer · 2021Article
- The Association of Human Papillomavirus in Benign and Malignant Laryngeal Lesions-a Pilot Study.Indian journal of surgical oncology · 2021Article
- Article
- Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature.Oncology research · 2021Review
- CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.Journal of cancer research and clinical oncology · 2020Article
- Role of human papillomavirus infection in the etiology of vulvar cancer in Italian women.Infectious agents and cancer · 2020Article
- Response: Letter regarding "The prognostic value of p16 and p53 expression for survival after vulvar cancer: A systematic review and meta-analysis".Gynecologic oncology reports · 2019Article
- LRIG1‑2 and LMO7 immunoreactivity in vulvar squamous cell carcinoma: Association with prognosis in relation to HPV‑DNA and p16INK4a status.Oncology reports · 2019Article
- Overexpression of p16Frontiers in oncology · 2019Article
- Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology.Oncotarget · 2017Article
- PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.Oncotarget · 2017Article
- Local immune response depends on p16INK4a status of primary tumor in vulvar squamous cell carcinoma.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to evaluate the correlation between p16(ink4a)-overexpression and high risk (hr)HPV-DNA in vulvar squamous cell carcinoma (vSCC) tumors as well as the impact of both biomarkers on the prognosis of vSCC patients.
methodsPCR-detection of (hr)HPV-DNA and immunohistochemical staining for p16(ink4a) were conducted in 85 vSCC tumors. Survival analyses included the Kaplan-Meier method, log-rank test and Cox proportional hazards model.
resultsp16(ink4a)-overexpression and (hr)HPV-DNA were detected in 35 and 37 of the 85 tumors, respectively. Among the 35 p16(ink4a)-positive tumors, 10 lacked (hr)HPV-DNA (29 %). Among the 50 p16(ink4a)-negative tumors, (hr)HPV-DNA was detected in 12 cases (24 %). The median follow-up was 89.20 months (range 1.7-189.5 months). P16(ink4a)-overexpression, but not (hr)HPV-DNA positivity of the primary tumor, was correlated with prolonged overall survival (OS) (p = 0.009). P16(ink4a)-overexpression predicted a better response to radiotherapy (p < 0.001). Univariate analysis has demonstrated that age (p = 0.025), tumor grade (p = 0.001), lymph node metastasis (p < 0.001), FIGO stage (p < 0.001), p16(ink4a)-overexpression (p = 0.022), and adjuvant RTX (p < 0.001) were prognostic factors for OS. Multivariate analysis has demonstrated that lymph node metastasis (HR 1-2.74, 95 % CI 1.50-5.02, p = 0.019), tumor grade (HR 1-2.80, 95 % CI 1.33-5.90, p = 0.007) and p16(ink4a)-overexpression (HR 1-2.11, 95 % CI 1.13-3.95, p = 0.001) are independent prognostic factors.
conclusionThe discovered overlap suggests the use of p16(ink4a) in combination with HPV-DNA detection as an ancillary test for future research and clinical studies in vSCC. The prognostic and predictive value of p16(ink4a)-overexpression should be tested in larger cohort studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.